CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. Issue 11 (November 2018)

• Record Type: Journal Article
• Authors: Alcantara, Marion; Tesio, Melania; June, Carl; Houot, Roch
• Is Part Of: Leukemia. Volume 32:Issue 11(2018)
• Page Start: 2307
• Page End: 2315
• Publication Date: 2018-11
• Subjects: Leukemia -- Periodicals; 616.99419
• DOI: 10.1038/s41375-018-0285-8
• Languages: English
• ISSNs: 0887-6924

Abstract

Abstract Chimeric antigen receptor (CAR) T-cells targeting CD19 demonstrated remarkable efficacy for the treatment of B-cell malignancies. The development of CAR T-cells against T-cell malignancies appears more challenging due to the similarities between the therapeutic, normal and malignant T-cells. The obstacles include CAR T-cell fratricide, T-cell aplasia, and contamination of CAR T-cell products with malignant T-cells. Here, we review these challenges and propose solutions to overcome these limitations.